Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2018
Mar. 31, 2018
Current assets    
Cash and cash equivalents $ 479,700 $ 732,542
Restricted cash 15,912 5,692
Marketable securities 2,573,605 8,304,392
Other current assets and prepaid expenses 85,710 59,249
Total current assets 3,154,927 9,101,875
Licensing right to use technology 495,000
Property and equipment, net 259,221 253,184
TOTAL ASSETS 3,909,148 9,355,059
Current liabilities    
Accounts payables 833,732 842,039
Accrued expenses 324,599 1,290,886
Options to be issued to NitricGen 295,000
Total current liabilities 1,453,331 2,132,925
Liabilities related to warrants 5,677,934
Long-term liabilities 1,453,331 7,810,859
Commitments and contingencies
Shareholders' equity    
Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2018 and March 31, 2018, respectively
Common Stock, $0.0001 par value per share: 100,000,000 shares authorized, 8,533,657 and 8,397,056 shares issued and outstanding as of December 31, 2018 and March 31, 2018, respectively 853 840
Treasury stock (25,000) (25,000)
Additional paid-in capital 40,056,458 32,141,110
Accumulated deficit (37,586,650) (30,569,764)
Accumulated other comprehensive income (loss) 10,156 (2,986)
Total shareholders' equity 2,455,817 1,544,200
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 3,909,148 $ 9,355,059